Steven Cohen's position in Crinetics Pharmaceuticals is currently worth $225 Million. That's 0.70% of their equity portfolio (22nd largest holding). The investor owns 5.86% of the outstanding Crinetics Pharmaceuticals stock. The first Crinetics Pharmaceuticals trade was made in Q3 2019. Since then Steven Cohen bought shares ten more times and sold shares on eight occasions. The stake costed the investor $126 Million, netting the investor a gain of 78% so far.